Epidyolex 100 mg/ml oral solution

DRUG3 trials

Sponsors

Region Hovedstaden, Amsterdam UMC Stichting, Assistance Publique Hopitaux De Paris

Conditions

Children and adolescents with severe neurodevelopmental disordersFragile X syndrome (FXS)Lifetime cannabis useNon-affective psychosisSanfilippo syndromeTuberous Sclerosis Complex (TSC)

Phase 2

Cannabidiol for treatment of non-affective psychosis and cannabis use

CompletedCTIS2024-517630-18-00

Region HovedstadenLifetime cannabis use, Non-affective psychosis

Start: 2024-10-08End: 2025-12-02Target: 64Updated: 2025-03-11

CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders

Not yet recruitingCTIS2025-521161-27-00

Assistance Publique Hopitaux De ParisChildren and adolescents with severe neurodevelopmental disorders

Target: 21Updated: 2025-10-07

Phase 3

Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series

Not yet recruitingCTIS2025-520846-31-00

Amsterdam UMC StichtingFragile X syndrome (FXS), Sanfilippo syndrome, Tuberous Sclerosis Complex (TSC)

Target: 30Updated: 2025-10-30